Skip to content
2000
Volume 1, Issue 2
  • ISSN: 2214-0832
  • E-ISSN: 2214-0840

Abstract

Resistance of malignant cells to chemotherapy and molecularly targeted therapy is a major roadblock in our effort to cure cancer. A variety of underlying mechanisms have been described, some of which are shared between resistance to chemotherapy and resistance to molecularly targeted therapy. Although the influence of genetic mutations in the development of drug resistance is beyond question, many examples now support the contribution of epigenetic changes to drug resistance. Several clinical trials are under way to explore the effectiveness of epigenetics-targeting drugs to reverse or overcome resistance to cancer therapies. In addition to these strategies, we suggest a complementary approach that could utilize epigenetics-targeting drugs to prevent drug resistance.

Loading

Article metrics loading...

/content/journals/edt/10.2174/221408320102160315154731
2015-08-01
2025-02-17
Loading full text...

Full text loading...

/content/journals/edt/10.2174/221408320102160315154731
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test